RT Journal Article
SR Electronic
T1 Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey
JF RMD Open
JO RMD Open
FD EULAR
SP e002587
DO 10.1136/rmdopen-2022-002587
VO 8
IS 2
A1 Michael DiIorio
A1 Kevin Kennedy
A1 Jean W Liew
A1 Michael S Putman
A1 Emily Sirotich
A1 Sebastian E Sattui
A1 Gary Foster
A1 Carly Harrison
A1 Maggie J Larché
A1 Mitchell Levine
A1 Tarin T Moni
A1 Lehana Thabane
A1 Suleman Bhana
A1 Wendy Costello
A1 Rebecca Grainger
A1 Pedro M Machado
A1 Philip C Robinson
A1 Paul Sufka
A1 Zachary S Wallace
A1 Jinoos Yazdany
A1 Monique Gore-Massy
A1 Richard A Howard
A1 More A Kodhek
A1 Nadine Lalonde
A1 Laura-Ann Tomasella
A1 John Wallace
A1 Akpabio Akpabio
A1 Deshiré Alpízar-Rodríguez
A1 Richard P Beesley
A1 Francis Berenbaum
A1 Inita Bulina
A1 Eugenia Yupei Chock
A1 Richard Conway
A1 Alí Duarte-García
A1 Eimear Duff
A1 Tamer A Gheita
A1 Elizabeth R Graef
A1 Evelyn Hsieh
A1 Lina El Kibbi
A1 David FL Liew
A1 Chieh Lo
A1 Michal Nudel
A1 Aman Dev Singh
A1 Jasvinder A Singh
A1 Namrata Singh
A1 Manuel F Ugarte-Gil
A1 Jonathan S Hausmann
A1 Julia F Simard
A1 Jeffrey A Sparks
YR 2022
UL http://rmdopen.bmj.com/content/8/2/e002587.abstract
AB Objective We investigated prolonged COVID-19 symptom duration, defined as lasting 28 days or longer, among people with systemic autoimmune rheumatic diseases (SARDs).Methods We analysed data from the COVID-19 Global Rheumatology Alliance Vaccine Survey (2 April 2021–15 October 2021) to identify people with SARDs reporting test-confirmed COVID-19. Participants reported COVID-19 severity and symptom duration, sociodemographics and clinical characteristics. We reported the proportion experiencing prolonged symptom duration and investigated associations with baseline characteristics using logistic regression.Results We identified 441 respondents with SARDs and COVID-19 (mean age 48.2 years, 83.7% female, 39.5% rheumatoid arthritis). The median COVID-19 symptom duration was 15 days (IQR 7, 25). Overall, 107 (24.2%) respondents had prolonged symptom duration (≥28 days); 42/429 (9.8%) reported symptoms lasting ≥90 days. Factors associated with higher odds of prolonged symptom duration included: hospitalisation for COVID-19 vs not hospitalised and mild acute symptoms (age-adjusted OR (aOR) 6.49, 95% CI 3.03 to 14.1), comorbidity count (aOR 1.11 per comorbidity, 95% CI 1.02 to 1.21) and osteoarthritis (aOR 2.11, 95% CI 1.01 to 4.27). COVID-19 onset in 2021 vs June 2020 or earlier was associated with lower odds of prolonged symptom duration (aOR 0.42, 95% CI 0.21 to 0.81).Conclusion Most people with SARDs had complete symptom resolution by day 15 after COVID-19 onset. However, about 1 in 4 experienced COVID-19 symptom duration 28 days or longer; 1 in 10 experienced symptoms 90 days or longer. Future studies are needed to investigate the possible relationships between immunomodulating medications, SARD type/flare, vaccine doses and novel viral variants with prolonged COVID-19 symptoms and other postacute sequelae of COVID-19 among people with SARDs.Data are available on reasonable request. Researchers interested in performing additional analyses from survey data are invited to submit proposals through the COVID-19 Global Rheumatology Alliance at rheum-covid.org. For approved projects, we will be able to provide summary tables and data analyses as requested. We do not currently have institutional review board approval to make the raw data available to other researchers.